Posted August 13, 2021
The FDA has delayed implementation of a bad rule that will limit access to customized medicines like bioidentical estriol and progesterone that millions of women rely on. Action Alert!   The FDA recently announced that it will extend by one year — to October 27, 2022 — the date on which it will begin enforcement of the Memorandum of Understanding (MOU) with states regarding interstate shipments of compounded medications. This is a direct result of ANH and other stakeholder advocacy on this issue.  Read more.